Drug intelligence / Profile preview

MT-501

Development stage: Phase 2
Lead developer: Mirador Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

MT-501 is an orally available investigational small molecule drug being developed by Mirador Therapeutics. It is currently in Phase 1 clinical trials, with its first-in-human study evaluating safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy adult volunteers. The specific mechanism of action has not been disclosed. MT-501 is being developed for the treatment of chronic immune-mediated inflammatory and fibrotic diseases, leveraging Mirador's proprietary Mirador360 platform technology.

Other names: MT 501MT501MT-501

Beyond the preview

Go deeper on MT-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-501.

Explore the full profile